It looks like Big Pharma is getting over itself. It's restoring flow to its pipeline. Gloom-and-doom headlines are fading. In short, Big Pharma had become "haughty," says Albert Wertheimer, professor at Temple's School of Pharmacy. "They thought new mass market products would sustain them." Now, the industry is in the midst of regrouping. Companies are already concentrating on five or six areas of specialty. Pfizer lists 10, among them several that may not be mass-market drugs but will still have huge markets. "We'll see exciting things from Big Pharma in a little while," Wertheimer said.